Decreased frequency of HLA-DR13DR6 in Wegener's granulomatosis  by Hagen, E. Christiaan et al.
Kidney International, Vol. 48 (1995), pp. 801—805
Decreased frequency of HLA-DR13DR6 in
Wegener's granulomatosis
E. CHRISTIAAN HAGEN, COEN A. STEGEMAN, JOE D'AMARO, GEZIENA M.T. SCHREUDER,
SIMON P.M. LEMS, J WILLEM COHEN TERVAERT, Gus M.TH.DE JONG, RONALD J. HENE,
CEES G.M. KALLENBERG, MOHAMMED R. DAHA, and Foio J. VAN DER WOUDE
Departments of Nephrology and Immunohematology and Bloodbank, University Hospital Leiden; Department of Nephrology, Clinical Immunology and
Laboratoiy for Transplantation Immunology, University Hospital Groningen; Department of Nephrology, Drechtsteden Hospita4 Dordrecht; and
Department of Nephrology, University Hospital Utrecht, The Netherlands
Decreased frequency of HLA-DR13DR6 in Wegener's granulomatosis.
The pathogenesis of Wegener's granulomatosis, microscopic polyangiitis
and idiopathic rapidly progressive glomerulonephritis (RPGN) is still
unclear; in vitro data support both humoral and cellular autoimmune
mechanisms. An association of Wegener's granulomatosis with HLA
antigens has been described, with conflicting results concerning the
antigens involved. We have performed serological 1-ILA typing of patients
at two different laboratories within the Netherlands (N = 118 and N =
106, respectively). A significant decrease in the frequency of HLA-
DR13DR6 was present in both patient groups in comparison to controls( = 21.9; corrected P value < 0.004 for both groups together). There
were no differences in the distribution of HLA-antigens between patients
with Wegener's granulomatosis and microscopic polyangiitis, between
cANCA (cytoplasmic anti-neutrophil cytoplasmic antibodies) and
pANcA (perinuclear ANCA, anti-MPO) positive patients, and between
patients with and without relapsing disease.
Wegener's granulomatosis and microscopic polyangiitis are
both characterized by systemic vasculitis of small arteries, capil-
lanes and veins [1]. In both diseases, crescentic necrotizing
glomerulonephritis (CNGN) with few or no immune deposits
(pauci-immune CNGN) is frequently found. In Wegener's gran-
ulomatosis, necrotizing granulomatous lesions are typically lo-
cated in the upper and lower respiratory tract, but may occur in
any organ of the body. In combination with vasculitis and CNGN
they form the classical histological triad of the disease, and
distinquish Wegener's granulomatosis from microscopic polyan-
giitis [1, 2]. Idiopathic RPGN represents a limited form of
microscopic polyangiitis, with comparable histopathology of the
kidney, but without the features of extrarenal vasculitic activity
[3].
Microscopic polyangiitis, Wegener's granulomatosis and idio-
pathic RPGN are associated with autoantibodies against neutro-
phils (ANCA, anti-neutrophil cytoplasmic antibodies) [3—51.
These antibodies are directed against enzymes in neutrophil
granules. Anti-proteinase-3 (PR3) antibodies are found in up to
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90% of patients with active generalized Wegener's granulomatosis
and in approximately 50% of microscopic polyangiitis patients [6].
Most other patients with microscopic polyangiitis have anti-
myeloperoxidase (MPO) antibodies, while patients with idio-
pathic RPGN have anti-MPO in even a higher frequency [7].
The high frequency of ANCA and their correlation with disease
activity have led to speculation about their pathogenic role in
systemic vasculitis. In vitro data have shown that these antibodies
can activate neutrophils, and may interfere with the function of
their target enzymes and inhibitors [8, 9]. In recent reports the
role of a T cell-driven autoimmune response was investigated; in
vitro studies have shown that lymphocytes from Wegener's gran-
ulomatosis patients can be stimulated into proliferation by neu-
trophil extracts and purified proteinase-3 [10—13].
Association of Wegener's granulomatosis and microscopic poly-
angiitis with certain HLA antigens has been reported in a number
of studies, with conflicting results. Most studies were performed in
a limited number of patients, and the HLA antigens associated
with Wegener's granulomatosis have varied [14—1 71, while in four
studies no association was present at all [18—21]. We have
investigated the frequency of HLA antigens in two large groups of
patients with Wegener's granulomatosis, microscopic polyangiitis
and idiopathic RPGN in the Netherlands. Data from both groups
were independently collected and HLA typed at two centers, and
the results of both groups were compared and combined.
Methods
Patients
Patients in group 1 (N = 118) were collected from three
university hospitals [Leiden (N = 57), Utrecht (N = 6), Amster-
dam (N = 12)], and one local hospital (N = 13). Furthermore,
some patients (N = 30) were contacted through the Dutch
Foundation for patients with Wegener's granulomatosis ("Fried-
erich Wegener Foundation"). Group 2 consisted of 106 patients
who were referred to the University Hospital Groningen (tertiary
referral center for vasculitis). Only unrelated Dutch Caucasoid
patients were included in both groups.
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Controls
As a control population 2443 unrelated Dutch Caucasoid
healthy blood donors were HLA-typed in Leiden with the same
methodology as used for the patients.
Diagnostic criteria
The following four patient subgroups were studied:
A. Wegener's granulomatosis with histological evidence of disease.
Classical histology consisting of (a) granulomas and vasculitis, or
granulomas with CNGN, or (b) no evidence of granulomas in a
biopsy but with definitive histology with CNGN or vasculitis in
combination with airway involvement compatible with Wegener's
granulomatosis (including chronic sinusitis, destructive nose le-
sions, pulmonary nodules, excluding diffuse pulmonary hemor-
rhage).
B. Clinical Wegener's granulomatosis without histological evi-
dence of disease. These patients had a clinical picture suggestive of
Wegener's, with a positive ANCA test (cANCA or pANDA with
specificity for anti-MPO). All patients had at least chronic inflam-
matory lesions of the upper airways with destruction not due to
infection (saddle nose, septum perforation, subglottic stenosis), or
fixed infiltrates/nodules in the lung.
C. Microscopic polyangiitis. This group was diagnosed with
necrotizing vasculitis affecting small vessels, in combination with
pauci-immune CNGN in a renal biopsy, without airway disease
suggestive of Wegener's granulomatosis (patients could have
diffuse pulmonary hemorrhage).
D. Idiopathic rapidly progressive glomerulonephritis. These pa-
tients had biopsy-proven pauci-immune CNGN with no evidence
of systemic vasculitic disease.
Patient records were reviewed for clinical data, including
localization of disease activity in the upper and the lower respi-
ratory tract, evidence of renal disease, skin lesions, peripheral
neuropathy, eye symptoms, or other symptoms related to vascu-
litis. ANCA serology was performed in an indirect immune
fluorescence assay [22]. The staining pattern was scored as
cANCA, pANCA, or negative. pANCA was always confirmed by
anti-MPO specific ELISA. cANCA antigenic specificity (anti-
proteinase-3) was not always available (anti-proteinase-3 specific
assays only became available in 1992). Biopsy reports were scored
for the presence of granulomas, vasculitis and/or glomerulone-
phritis. Relapses were scored (defined as disease activity requiring
increase of immunosuppressive therapy).
HLA typing
HLA typing for class I and II was performed in two centers by
serological methods using complement dependent microcytotox-
icity on peripheral blood lymphocytes. Both centers used locally
obtained typing reagents allowing the definition of most WHO
recognized HLA antigens. Besides typing for HLA-DR1-DR16,
controls and group 1 patients were typed for DQ1-DQ9, whereas
group 2 patients were typed for DQ1-DQ3 broad specificities
only. Both typing laboratories have shown to perform HLA typing
at consistently comparable high quality as assessed by regular
participation in proficiency testing programs.
Statistical analysis
Haldane's modification of Woolf's method was used to calcu-
late the Relative Risk (RR) and its significance in the single and
Table 1. Clinical and serological data for the patients in groups 1 and 2
Group
Diagnosis
WG cI-12% 1 WG MPA i2%1 2% 1 RPGN2 %
N 83 71 14 13 14 11 7 11
Mean age 57 50 57 62 53 55 66 48
Male/female ratio 1 1.4 0.8 2 1 0.2 1.3 1.8
Organ involvement
Ear/nose/throat 45 69 74 11 9 74 0 3 12 0 0 0
Lung 32 50 53 3 10 48 6 10 64 0 0 0
Kidney 62 51 73 6 12 67 14 10 96 7 11 100
Skin 30 49 51 3 8 41 6 2 32 0 0 0
Eye 33 23 36 9 3 44 5 1 24 0 0 0
Neuropathy 31 50 53 4 7 41 3 2 20 0 0 0
Serology
cANCA 70 67 89 13 13 96 9 0 36 6 2 44
pANCA 83 71 04 311 561 9 56
Negative 2 0 1 0 0 0 1 0 4 0 0 0
Unknown 3 1 3 0 0 0 1 0 4 0 0 0
Relapses 32 34 43 6 5 41 2 1 12 2 0 11
No relapses 49 37 56 7 8 56 12 10 88 5 11 89
Unknown 2 0 1 1 0 4 0 0 0 0 0 0
Abbreviations are: WG, Wegener's granulomatis with histological evi-
dence of disease; cl-WG, clinical Wegener's granulomatosis; MPA, micro-
scopic polyangiitis; iRPGN, idiopathic RPGN.
pooled studies [23, 24]. When indicated, P values were corrected
for multiple comparisons using Edwards' formula by: Pc = 1 — (1
— Pu),where Pu is the uncorrected and Pc the corrected P value
and n is the number of comparisons [25].
Results
Clinical diagnosis and ANCA serology
The frequencies of the diagnostic subgroups are shown in Table
1. A total of 181 patients (154 with histological evidence of
disease, 27 without histology) was diagnosed as Wegener's gran-
ulomatosis, 25 as microscopic polyangiitis and 18 as idiopathic
RPGN. There was a similar distribution of various diagnostic
categories in group 1 and 2.
The clinical features of the patients are shown in Table 1. As
expected respiratory tract [ear/nose/throat (ENT) and lung] in-
volvement was prominent in Wegener's granulomatosis patients.
Lung involvement in microscopic polyangiitis was mainly due to
alveolar hemorrhage. Three patients with microscopic polyangiitis
in group 2 had minor ENT symptoms, not sufficient to nominate
them as having Wegener's granulomatosis. ANCA serology was
positive in 97% of patients with Wegener's granulomatosis [90%
cANCA, 7% pANCA (anti-MPO)], 92% of patients with micro-
scopic polyangiitis [36% cANCA, 56% pANCA (anti-MPO)], and
100% of patients with idiopathic RPGN [44% cANCA, 56%
pANCA (anti-MPO)]. Relapses were most frequent in Wegener's
granulomatosis patients (43% of patients had 1 or more relapses,
mean follow-up time 77.5 months, whereas 12% of the micro-
scopic polyangiitis patients and 11% of the idiopathic RPGN
patients had one or more relapses and a mean follow-up time of
47.3 and 46.5 months, respectively).
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s 2 vs. controlsP c
Group 1 + 2
N = 224 Groups 1 + 2 vs. controls
x2 P, Pc x P, P
DR1 20 15 1.61 17 0.32 16 1.77
DR2 29 30 0.18 31 0.47 31 0.53
DR15 25 29 0.65 25 0.01 27 0.22
DR16 2 1 0.22 1 0.1 1 0.6
DR3 25 22 0.61 28 0.45 24 0.02
DR4 28 34 2.2 0.1 1 38 4.86 0.03 0.9 36 6.26 0.01 0.7
DR5 19 19 0.01 13 1.89 16 0.8
DRII 14 17 0.56 11 0.84 14 0.02
DR12 5 3 0.82 0.6 1 0 5.25 0.03 0.8 1 4.68 0.03 0.9
DR6 34 17 13.36 0.0005 0.047 19 9.24 0.003 0.20 18 21.93 0.00004 0.004
DR13 28 12 12.64 0.0007 0.06 10 15 0.0003 0.03 11 26.89 0.00001 0.001
DR14 5 5 0 7 0.65 6 0.21 0.7 1
DR7 19 24 1.93 16 0.48 20 0.23
DR8 5 7 0.86 7 0.61 7 1.08
DR9 2 2 0.04 1 0.56 1 0.69
DR1O 4 2 1.42 0.2 1 0 4.89 0.02 0.9 1 5.29 0.02 0.8
DR52 69 60 4.21 0.04 0.97 53 11.26 0.001 0.1 57 13.62 0.0005 0.04
DR53 46 51 1.29 41 0.98 46 0.02
DQI 71 54 14.53 0.0004 0.03 55 11.48 0.001 0.09 55 24.44 0.00002 0.00204
DQ5 36 23 6.95 0.008 0.5 not tested
DQG 48 37 3.76 not tested
DQ2 37 36 0.05 33 0.84 34 0.64
D03 49 56 1.72 52 0.35 54 1.77
DQ7 27 28 0.06 not tested
DQ8 20 20 0.01 not tested
DQ9 7 11 2.74 not tested
DQ4 4 7 2.23 not tested
Values are shown for group 1 and group 2 separately, and for the two groups together.
Abbreviations are: P, uncorrected P value; P Pvalue corrected for the number of comparisons made (see text); P values are only shown when P
<0.05 in one of the two groups.
HLA antigen frequencies
There were no significant differences for class I antigens in
groups 1 and 2, analyzed both separately and together (data not
shown). B5 and B51 were lower than in controls in group 2 (Pu <
0.03), but after correction for the number of comparisons this was
not significant. This finding could not be confirmed in group 1.
The frequencies of the tested HLA class II antigens are set out
in Table 2. There was a significant decrease in the frequency of
DR6 in group I as compared to controls (17% vs. 34%, RR 0.40,
< 0.0006, Pc < 0.05). This decrease was largely due to a
decreased frequency in one of the splits of DR6, namely DR13
(12% vs. 28%, RR 0.37, P, <0.0007, P = 0.061) while the other
split of DR6, DR 14, was similar in group 1 versus controls (5% vs.
5°0, 1u = 0.95, RR 1.0). The frequency of DR13DR6 associated
antigens (DQ1, DR52) was also lower (Table 2).
These findings could be confirmed in group 2. Both DR6 and its
split DR13 were lower by a similar magnitude as in group 1 (DR6:
19% vs. 34%, RR 0.47, u < 0.003, c = 0.22; DR13: 10% vs.
28%, RR 0.29, P < 0.0003, P < 0.03), as was DQ1; Table 2).
A comparison of the antigen frequencies between group 1 and
group 2 showed no significant frequency differences for any of the
antigens tested (data not shown). This justified a pooled analysis
of all patients in both groups (Table 2). As expected, DR6 and
DR13 were again significantly lower in patients than in controls
(P < 0.004, RR 0.43 and P < 0.002, RR 0.32, respectively).
DR6-linked alleles were lower as well (DR52, DQ1). DR4 was
higher, but after correction this difference was not significant (c
= 0.67, RR 1.4). Again, no difference was found in class I antigens
between patients and controls (data not shown).
Subgroup analysis
Table 3 shows the frequencies of DR6 and DR13 positive
patients in the different diagnostic groups of ANCA associated
diseases. There was no significant difference between the different
diagnostic categories (data not shown). In group 2, the DR13DR6
frequency was zero in the microscopic polyangiitis patients as
compared to 20% in the Wegener's granulomatosis patients, but
this difference was not statistically significant. In group 1
DR13DR6 was absent in idiopathic RPGN patients, but here
again the difference was not statistically significant.
No significant difference in antigen frequencies was found
between cANCA positive and pANCA (anti-MPO) positive pa-
tients, nor between patients with and without a history of relaps-
ing disease (data not shown).
Discussion
This study shows an association between the reduced frequency
or absence of DR13DR6 and ANCA-associated systemic vasculi-
tis. This association was established in two independently investi-
gated patient groups in the Netherlands. The decreased frequency
was found in patients with Wegener's granulomatosis. The fre-
quency of HLA-DR13DR6 in patients with microscopic polyan-
giitis and idiopathic RPGN was equally low, however, not signif-
icantly different from controls, probably due to the lower number
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Table 3. Analysis of DR6 and DRI3 frequencies in diagnostic sub-groups of ANCA associated diseases
Group 1 Group 2 Groups 1 + 2
N % positive P, N % positive P,, N % positive P
DR6
WG 97 17 0.001 84 20 0.01 181 19 0.0001
MPA 14 21 NS 11 0 0.01 25 12 0.03
IRPGN 7 0 NS 11 27 NS 18 19 0.2
All diagnoses 118 17 0.0005 106 19 0.002 224 18 0.00004
Controls 2443 34 2443 34 2443 34
DR13
WG 97 12 0.001 84 10 0.001 181 11 0.00003
MPA 14 21 NS 11 0 0.03 25 12 0.08
iRPGN 7 0 NS 11 18 NS 18 12 NS
All diagnoses 118 12 0.0007 106 10 0.0003 224 11 0.00001
Controls 2443 28 2443 28 2443 28
Abbreviations are: P, uncorrected P value for comparison between DR6 or DR13 positive patients and controls; WG, Wegener's granulomatosis
(including clinical Wegener's granulomatosis); MPA, microscopic polyangiitis; iRPGN, idiopathic rapidly progressive glomerulonephritis.
of patients in these categories. There was no difference in HLA
antigen frequencies between cANCA and pANCA positive pa-
tients and between patients with or without relapses.
Previous studies concerning HLA antigens and systemic vascu-
litis have yielded conflicting results. Earlier studies have indicated
an association with HLA-B7 (N = 25) [19], HLA-B8 (N = 25,N =
31) [15, 19] and HLA-DR2 (N = 17) [14] with Wegener's
granulomatosis. Two studies failed to find an association of HLA
antigens and Wegener's granulomatosis (N = 31,N = 41) [18, 20].
Some of these earlier studies investigated only a limited number
of HLA antigens. Furthermore, most studies investigated a rela-
tively low number of patients (between 17 and 51 patients). More
recently, with the use of molecular typing techniques, an associ-
ation was found with increased frequencies of DRI -DOl (N =27)
[17] and with DQ7 (N = 59) [16]. The latter study further
indicated a decreased frequency of DR3 and a relation of
persistent ANCA positivity with DR2, while patients with tran-
sient positivity for ANCA were more likely to have DQ7. Zhang
et al reported on DNA-typing of HLA class II in 94 patients [21].
They could not find a significant correlation with any of the
antigens tested.
Significant negative correlations between vasculitis and HLA-
DR6 have until now not been reported. However Papiha et al
found DR6 to be absent in 27 patients tested (in contrast to 15%
in their control population, this was reported as not significant
after correction) [17]. Elkon et al [14] reported the absence of
DR6 in 17 Wegener's granulomatosis patients and 14 Churg-
Strauss patients. These authors did not report on the significance
of this finding. Spencer et al did not find a difference in DR6
frequencies between patients and controls [16]. We could not
confirm the positive correlation with D07 (only tested in group I
in this study), nor with DR1-DQ1 as reported earlier.
The implications of this finding for our understanding of the
pathogenesis of these diseases may have to do with the induction
of autoreactive T cells. The pathogenesis of Wegener's granulo-
matosis, microscopic polyangiitis and idiopathic RPGN remains
unclear. These diseases are considered to have common patho-
genic mechanisms because they are all strongly associated with
antibodies against neutrophil cytoplasmic constituents [26]. In-
flammatory infiltrate analysis indicate the abundant presence of
CD4-positive T cells [27]. Results of in vitro experiments investi-
gating the role of the T cell in Wegener's granulomatosis have
been equivocal. Our group was the first to report positive in vitro
proliferation of peripheral lymphocytes from Wegener's granulo-
matosis patients with granulocyte extract [10]. This observation
was recently confirmed [Ii, 13], while others reported no differ-
ence in proliferation between patients and controls [281. Prolifer-
ation to isolated proteinase-3 has also been reported [12].
Our results suggest a protective role of HLA-DR13DR6 against
systemic vasculitis. One could speculate that HLA-DR13DR6
could present antigens derived from azurophilic granules and
thereby modulate the response of possibly autoreactive T cells.
Such a protective role of certain class II molecules is not without
precedent in autoimmune diseases. A negative association be-
tween a class II antigen and autoimmunity has also been reported
for insulin-dependent diabetes mellitus (IDDM). Apart from a
strong positive correlation between HLA-DR3 and -DR4 and
IDDM, there is also a strong negative correlation between DR2
and the disease [29, 30].
In conclusion, this study shows a negative association between
the presence of HLA-DRI3DR6 and the development of ANCA
positive systemic vasculitis and glomerulonephritis.
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